Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn

Cover Caption

About the Cover:  Color-coded computerized image maps showing, on a pixel-by-pixel basis, the percentages of animals with normal (i.e., noninfarcted) tissue at seven rostrocaudal coronal levels in vehicle-treated (panel A, n = 11) and STAZN-treated animals (panel B, n = 16) (see text for details of image mapping). See the article by Ley et al. on page 1090 of this issue.

Back to top
PreviousNext

In this issue

Journal of Pharmacology and Experimental Therapeutics: 313 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 313, Issue 3
1 Jun 2005
  • Table of Contents
  • About the Cover
  • Index by author
Sign up for alerts

Jump to

  • PERSPECTIVES IN PHARMACOLOGY
  • ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION
  • BEHAVIORAL PHARMACOLOGY
  • CARDIOVASCULAR
  • CELLULAR AND MOLECULAR
  • GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL
  • INFLAMMATION AND IMMUNOPHARMACOLOGY
  • NEUROPHARMACOLOGY
  • TOXICOLOGY
  • Most Read
Loading
  • Potential Clinical Uses of CBG
  • Ocular Drug Delivery: Past, Present, and Future
  • Nose-to-Brain Delivery
  • Antipsychotic-VMAT2 Inhibitor Synergy: Schizophrenia Models
  • SEP-363856, a Novel, Non-D2 Psychotropic Agent
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics